Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Paliperidone: the evidence of its therapeutic value in schizophrenia
Core Evidence, 08/17/09
Kantrowitz J et al. – Paliperidone is primarily metabolized and excreted renally, and thus may be of particular utility for patients with hepatic impairment. There is clear evidence that paliperidone is more efficacious than placebo in reducing the positive and negative symptoms of schizophrenia. In patients with schizophrenia, paliperidone has been shown to stabilize acute psychotic symptoms. There is some evidence that it can prevent relapse in stabilized patients. Studies on the cost effectiveness of paliperidone are needed. Most importantly, there are no trials comparing paliperidone directly with other second–generation antipsychotics. Until direct efficacy and cost effectiveness comparisons are made with risperidone, it is difficult to justify paliperidone use over risperidone. It will become even harder to justify when risperidone becomes available as a less expensive generic medication.
Related Articles
Auditory gating deficit to human voices in schizophrenia: A MEG study
Schizophrenia Research, 10/01/09
Relevance Score: 93%
Age at onset and cognition in schizophrenia: meta-analysis
British Journal of Psychiatry, 10/06/09
Relevance Score: 92%
Beyond symptom dimensions: Schizophrenia risk factors for patient groups derived by latent class analysis
Schizophrenia Research, 10/30/09
Relevance Score: 91%
Functional Magnetic Resonance Imaging of Inner Speech in Schizophrenia
Biological Psychiatry, 10/26/09
Relevance Score: 91%
Sensory Processing in Schizophrenia: Neither Simple nor Intact
Schizophrenia Bulletin, 10/19/09
Relevance Score: 91%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Olanzapine versus other atypical antipsychotics for schizophrenia
Cochrane Reviews, 03/22/10
Efficacy of Metformin and Topiramate in Prevention and Treatment of Second-Generation Antipsychotic-Induced Weight Gain
Annals of Pharmacotherapy, 03/22/10
(gamma)-Secretase as a Therapeutic Target in Alzheimer's Disease
Current Drug Targets, 03/22/10
Article Search
Sponsor
Sponsor


See Latest Articles


